Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Medicines and Healthcare products Regulatory Agency

- PMLiVE

UK to introduce new regulatory framework for point of care manufacturing

The framework will make it easier for medicines to be made at or near hospitals

- PMLiVE

Takeda’s all-oral multiple myeloma triplet therapy recommended by NICE

Ninlaro with lenalidomide and dexamethasone improved clinical outcomes

- PMLiVE

Takeda therapy shows promise in rare blood clotting disorder

Phase 3 results show the enzyme replacement therapy reduced thrombocytopenia events by 60%

- PMLiVE

Takeda to acquire Nimbus’ TYK2 inhibitor in deal worth $6bn

NDI-034858 is under evaluation for the treatment of multiple autoimmune diseases

- PMLiVE

Takeda’s dengue vaccine receives EC approval

The decision follows a positive recommendation for Qdenga from the CHMP in October

- PMLiVE

Takeda’s Exkivity receives NICE recommendation for rare form of lung cancer

Patients with EGFR Exon20ins+ NSCLC make up approximately 2% of NSCLC cases

- PMLiVE

Takeda’s dengue vaccine candidate recommended for approval by CHMP

Dengue disease causes around 390 million infections and 500,000 hospitalisations each year

- PMLiVE

MHRA and NICE awarded £1.8m to explore regulation of digital mental health tools

The funding will go towards improving regulatory certainty and safety for mental health products

- PMLiVE

Takeda and Daiichi Sankyo collaborate to create wearable device

Takeda and Daiichi Sankyo have announced that they will work on a new research project, along with Tohoku University and MICIN, a digital health and telemedicine company, to develop a...

Takeda agrees on $2bn deal with Code Bio to expand its gene therapy programmes

The pharma company will gain opt-in rights for four rare diseases candidates

- PMLiVE

FDA rejects Takeda’s Eohilia after delays

After more than a year on ‘priority review’, the FDA has said it cannot approve Takeda’s budesonide oral suspension without a further clinical study

regeneron headquarters

UK approves Regeneron’s COVID-19 antibody cocktail

Ronapreve is the first monoclonal antibody therapy against COVID-19 approved in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links